In contrast to PTs, multivariable analyses of CD169+ LNMs showed both stronger HRs and stronger correlation to decreased risk of death from breast cancer, while evidence for TLLS infiltration being an independent prognostic factor decreased (HR CD169 = 0.48, 95%CI: (0.23–0.99), p = 0.046; HR TLLS = 0.72, 95%CI: (0.40–1.31), p = 0.28) compared to their univariable effects (HR CD169 = 0.59, 95%CI: (0.37–0.93), p = 0.025; HR TLLS = 0.66, 95%CI: (0.41–1.06), p = 0.085) (Figure S3D,F). Here, SIGLEC1 is linked to breast cancer.